EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced that EyePoint Pharmaceuticals will present at the following upcoming conferences.
WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:
- H.C. Wainwright 24th Annual Global Investment Conference
Forum: Corporate Presentation
Date: Monday, September 12, 2022
Time: 7:00 a.m. ET
- Baird 2022 Global Healthcare Conference
Forum: Corporate Presentation
Date: Wednesday, September 14, 2022
Time: 1:25 p.m. ET
- Guggenheim Nantucket Therapeutics Conference
Forum: Fireside Chat
Date: Thursday, September 29, 2022
Time: 10:30 a.m. ET
- Benzinga Retail Conference (Virtual)
Forum: Fireside Chat
Date: Friday, September 30, 2022
Time: 11:40 a.m. ET
A webcast and subsequent archived replay of the corporate presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Investors:
Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com
Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
